Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 266-273

  Muro, Eva P ^a   Fillekes, Quirine ^b   Kisanga, Elton R ^a   L'homme, Rafaëlla ^b   Aitken, Susan C ^c   Mariki, Godfrey ^d   Van Der Ven, Andre J A M ^b   Dolmans, Wil ^b   Schuurman, Rob ^c   Sarah Walker, A ^e   Gibb, Diana M ^e   Burger, David M ^b  

^a KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Pasua Antenatal Clinic   (Tanzania)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Africa; Carbamazepine; Nevirapine; Pharmacokinetics; Prevention of mother to child transmission of HIV

Indexed keywords

CARBAMAZEPINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ARTICLE; BIOCHEMISTRY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENETIC RESISTANCE; HEMATOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAPARTUM CARE; LABOR ONSET; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERINATAL INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS LOAD;

ADOLESCENT; ADULT; CARBAMAZEPINE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; YOUNG ADULT;

EID: 84859780444     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824234d8     Document Type: Article

References (36)

1. De Cock KM, Fowler MG, Mercier E, et al. Prevention of motherto-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283: 1175-1182. (Pubitemid 30126606)
2. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of motherto-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354: 795-802. (Pubitemid 29415583)
3. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of motherto-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362: 859-868. (Pubitemid 37130095)
4. L'homme RF, Dijkema T, van der Ven AJ, et al. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43: 193-196. (Pubitemid 44454813)
5. Muro E, Droste JA, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39: 419-421. (Pubitemid 41003786)
6. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38: 283-288. (Pubitemid 40333492)
7. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356: 135-147. (Pubitemid 46089674)
8. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4: 59-63. (Pubitemid 34808781)
9. Eshleman SH, Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of motherto- child transmission of HIV-1. J Infect Dis. 2006;193: 479-481. (Pubitemid 43202737)
10. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192: 16-23. (Pubitemid 40863852)
11. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis. 2008;46: 611-621. (Pubitemid 351263504)
12. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiencyvirus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002;186: 181-188. (Pubitemid 34765505)
13. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007;21: 957-964. (Pubitemid 46684327)
14. Flys TS, McConnell MS, Matovu F, et al. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis. 2008; 198: 465-469.
15. McConnell M, Bakaki P, Eure C, et al. Effectiveness of repeat singledose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr. 2007;46: 291-296. (Pubitemid 350287355)
16. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15: 1951-1957. (Pubitemid 32980636)
17. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single- dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. 2004; 20: 595-599. (Pubitemid 38813656)
18. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis. 2010; 50: 898-908.
19. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis. 2006;193: 482-487. (Pubitemid 43202738)
20. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother. 2007;51: 896-901. (Pubitemid 46355273)
21. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007;370: 1698-1705. (Pubitemid 350100773)
22. Chi BH, Chintu N, Cantrell RA, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr. 2008;48: 220-223.
23. Arrive E, Chaix ML, Nerrienet E, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS. 2009;23: 825-833.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2009. Top HIV Med. 2009;17: 138-145.
25. Hollanders RM, van Ewijk-Beneken Kolmer EW, Burger DM, et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;744: 65-71. (Pubitemid 30412051)
26. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13: 479-486.
27. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother. 2009;63: 170-177.
28. Bar-Oz B, Nulman I, Koren G, et al. Anticonvulsants and breast feeding: a critical review. Paediatr Drugs. 2000;2: 113-126. (Pubitemid 30167296)
29. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292: 202-209. (Pubitemid 38917997)
30. Sherman GG, Jones SA, Coovadia AH, et al. PMTCT from research to reality-results from a routine service. S Afr Med J. 2004;94: 289-292. (Pubitemid 38585224)
31. Ayouba A, Nerrienet E, Menu E, et al. Mother-to-child transmission of human immunodeficiency virus type 1 in relation to the season in Yaounde, Cameroon. Am J Trop Med Hyg. 2003;69: 447-449. (Pubitemid 38248282)
32. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007; 36: 1009-1021. (Pubitemid 350018545)
33. Weinberg A, Forster-Harwood J, McFarland EJ, et al. Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol. 2009;45: 39-42.
34. Manzi M, Zachariah R, Teck R, et al. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health. 2005; 10: 1242-1250. (Pubitemid 41789677)
35. Jones SA, Sherman GG, Varga CA. Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa. AIDS Care. 2005;17: 466-470. (Pubitemid 40663206)
36. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol. 2007;21: 176-181. (Pubitemid 350194377)